MedTrace Logo

Effect of Targeting Upper Normal Serum Magnesium Levels on Norepinephrine Requirements in Septic Shock Patients

NCT07716956 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-07-21

No results posted yet for this study

Summary

The goal of this clinical trial is to assess the effect of targeting upper normal serum magnesium levels on norepinephrine requirements in adult patients with septic shock.

The main questions it aims to answer are:

1. Does maintaining upper normal serum magnesium levels lower the total cumulative dose and duration of norepinephrine therapy?
2. Does this approach reduce the intensive care unit (ICU) length of stay, duration of mechanical ventilation and mortality?

This study will compare an intervention group to a control group to see the effect of targeting upper normal serum magnesium levels.

Participants will:

* Have their serum magnesium levels assessed at baseline (Day 0), at three-day intervals (Days 3, 6, 9) thereafter and on the day of norepinephrine discontinuation.
* Receive individualized intravenous magnesium sulfate infusions to achieve and maintain the target serum magnesium levels.
* Have their demographic data collected and be monitored closely for clinical data, vital signs, Mean Arterial Pressure (MAP), urine output and laboratory parameters.

Conditions

Interventions

DRUG

magnesium sulfate

Intravenous magnesium sulfate infusions will be individualized and administered to achieve and maintain the target serum magnesium levels.

OTHER

standard care treatment

Patients will receive standard care required to maintain the target serum magnesium levels.

Sponsors & Collaborators

  • Alexandria University

    lead OTHER

Principal Investigators

  • Noha A Hamdy, PhD · Faculty of Pharmacy, Alexandria University.

  • Marwan M ElBourini, PhD · University of Alexandria

  • Asmaa K Elharony, PharmD · Faculty of Pharmacy, Alexandria University.

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-31
Primary Completion
2027-04-30
Completion
2027-07-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07716956 on ClinicalTrials.gov